Integrin Research The Martin Humphries Lab

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Hospitalized COVID-19 sufferers usually current with a big spectrum of scientific signs. There’s a vital want to raised perceive the immune responses to SARS-CoV-2 that result in both decision or exacerbation of the scientific illness. Right here, we study longitudinal plasma samples from hospitalized COVID-19 sufferers with differential scientific consequence. We carry out immune-repertoire evaluation together with cytokine, hACE2-receptor inhibition, neutralization titers, antibody epitope repertoire, antibody kinetics, antibody isotype and antibody affinity maturation towards the SARS-CoV-2 prefusion spike protein.

Deadly circumstances reveal excessive plasma ranges of IL-6, IL-8, TNFα, and MCP-1, and sustained excessive share of IgA-binding antibodies to prefusion spike in contrast with non-ICU survivors. Illness decision in non-ICU and ICU sufferers associates with antibody binding to the receptor binding motif and fusion peptide, and antibody affinity maturation to SARS-CoV-2 prefusion spike protein. Right here, we offer perception into the immune parameters related to scientific illness severity and disease-resolution consequence in hospitalized sufferers that would inform improvement of vaccine/therapeutics towards COVID-19.

Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based evaluation

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are systemic necrotizing vasculitides related to important morbidity and mortality. Given the immunosuppression used to handle these situations, it will be important for clinicians to acknowledge issues, particularly infectious ones, which can come up throughout therapy. Kaposi sarcoma (KS) is a lymphoangioproliferative neoplasm attributable to human herpes virus 8 (HHV-8). Its cutaneous manifestations can mimic vasculitis.

We describe a 77-year-old man with microscopic polyangiitis with pulmonary-renal syndrome handled with prednisone and intravenous cyclophosphamide who developed KS (HHV-Eight constructive) after 2 months of therapy. Cyclophosphamide was discontinued and prednisone step by step lowered with enchancment and scientific stabilization of KS lesions.

This complete evaluation contains all revealed circumstances of KS in sufferers with AAV, with a aim to summarize potential danger components together with the scientific traits of vasculitis, therapy and outcomes of sufferers with this uncommon complication of immunosuppressive remedy. We additionally expanded our literature evaluation to KS in different types of systemic vasculitis. Our case-based evaluation emphasizes the significance of contemplating infectious issues of immunosuppressive remedy, particularly glucocorticoids, and highlights the uncommon affiliation of KS in systemic vasculitis.

Aggressive Immunoassay of SARS-CoV-2 Utilizing Pig Sera-Derived Anti-SARS-CoV-2 Antibodies

Anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) nucleoprotein (NP) antibodies have been remoted from pig sera utilizing human SARS-CoV-2 NP-immobilized magnetic beads. The binding properties of the remoted antibodies towards SARS-CoV-2 NP have been examined by way of movement cytometry utilizing SARS-CoV-2 NP-immobilized magnetic beads. A aggressive immunoassay was developed for detecting SARS-CoV-2 NP in addition to SARS-CoV-2 within the tradition fluid utilizing magnetic beads with immobilized anti-SARS-CoV-2 NP antibodies. Selectivity assessments have been carried out throughout the aggressive immunoassay for SARS-CoV, MERS-CoV, and CoV pressure 229E within the tradition fluid.

Discount in Nesfatin-1 Ranges within the Cerebrospinal Fluid and Elevated Nigrostriatal Degeneration Following Ventricular Administration of Anti-nesfatin-1 Antibody in Mice

Nesfatin-1 is one among a number of brain-gut peptides which have a detailed relationship with the central dopaminergic system. Our earlier research have proven that nesfatin-1 is able to defending nigral dopaminergic neurons towards 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. A current research additionally revealed a diminished blood degree of nesfatin-1 in sufferers with Parkinson’s illness (PD). The present research was designed to analyze whether or not diminished nesfatin-1 in cerebrospinal fluid (CSF) induces nigrostriatal system degeneration.

An intra-cerebroventricular (ICV) injection approach was used to manage anti-nesfatin-1 antibody straight into the lateral ventricle of the mind. Enzyme-linked immunosorbent assay (ELISA) outcomes confirmed that ICV injection of anti-nesfatin-1 antibody into the lateral ventricle of the mind as soon as day by day for two weeks precipitated a major discount in nesfatin-1 ranges within the CSF (93.1%).

Remedy with anti-nesfatin-1 antibody resulted in a considerable loss (23%) of TH-positive (TH+) dopaminergic neurons within the substantia nigra pars compacta (SNpc), as proven by immunofluorescence staining, a depletion in dopamine and its metabolites within the striatum detected by high-performance liquid chromatography (HPLC), and apparent nuclear shrinkage and mitochondrial lesions in dopaminergic neurons within the SNpc detected by transmission electron microscopy (TEM).

Moreover, the outcomes from our Western blot and ELISA experiments demonstrated that anti-nesfatin-1 antibody injection induced an upregulation of caspase-Three activation, elevated the expression of p-ERK, and elevated brain-derived neurotrophic issue (BDNF) ranges within the SNpc. Taken collectively, these observations recommend that diminished nesfatin-1 within the mind could induce nigrostriatal dopaminergic system degeneration; this impact could also be mediated by way of mitochondrial dysfunction-related apoptosis. Our information help a task of nesfatin-1 in sustaining the conventional physiological perform of the nigrostriatal dopaminergic system.

Convergent antibody evolution and clonotype enlargement following influenza virus vaccination

Current advances in high-throughput single cell sequencing have opened up new avenues into the investigation of B cell receptor (BCR) repertoires. On this research, PBMCs have been collected from 17 human contributors vaccinated with the split-inactivated influenza virus vaccine throughout the 2016-2017 influenza season. A mix of Immune Repertoire Seize (IRCTM) expertise and IgG sequencing was carried out on ~7,800 plasmablast (PB) cells and preferential IgG heavy-light chain pairings have been investigated. In some contributors, a single expanded clonotype accounted for ~22% of their PB BCR repertoire.

Roughly 60% (10/17) of contributors skilled convergent evolution, possessing public PBs that have been elicited independently in a number of contributors. Binding profiles of 1 non-public and three public PBs confirmed they have been all subtype-specific, cross-reactive hemagglutinin (HA) head-directed antibodies.

Anti-RANKL Neutralizing Antibody
100874-2	BPS Bioscience	100 µg	EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-PCSK9 Neutralizing Antibody
71207	BPS Bioscience	50 µg	EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody
71340	BPS Bioscience	100 µg	EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43	ACROBIOSYSTEMS	100ug	EUR 2354
Description: Anti-BCMA Neutralizing Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with BCMA.

Anti-PD-1 Neutralizing Antibody
71120	BPS Bioscience	100 µg	EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-IL-17A Neutralizing Antibody
91015	BPS Bioscience	100 µg	EUR 490
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species.

Anti-β-Amyloid Neutralizing Antibody
71223	BPS Bioscience	100 µg	EUR 465
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species.

Anti-CTLA4 (CD152) Neutralizing Antibody
71212	BPS Bioscience	100 µg	EUR 490
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species.

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody
abx411283-02mg	Abbexa	0.2 mg	EUR 678

Anti-PD-L1 (CD274) Neutralizing Antibody
71213	BPS Bioscience	100 µg	EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)
abx411284-01mg	Abbexa	0.1 mg	EUR 610.8

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody
DL99728A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody
DL99728A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody
DL99729A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody
DL99729A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

human anti-CPV neutralizing mAb
E4A09V04	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

human anti-FPV neutralizing mAb
E4A09V05	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody
DL99725A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody
DL99725A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Anti-COVID-19 S-IgM Neutralizing Antibody
E38A9973	EnoGene	100ug/100ul	EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-IgA Neutralizing Antibody
E38A9974	EnoGene	100ug/100ul	EUR 225
Description: Available in various conjugation types.

Interferon alpha Neutralizing Antibody
20-abx137013	Abbexa	EUR 427.20 EUR 627.60	0.5 mg 1 mg

Anti-COVID-19 S-hIgG1 Neutralizing Antibody
E38A9970	EnoGene	100ug/100ul	EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-mIgG1 Neutralizing Antibody
E38A9971	EnoGene	100ug/100ul	EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-cIgG1 Neutralizing Antibody
E38A9972	EnoGene	100ug/100ul	EUR 225
Description: Available in various conjugation types.

human anti-FPV/CPV neutralizing mAb
E409C40-h100	EnoGene	100μL	EUR 395
Description: Available in various conjugation types.

Anti-2019-nCoV S-IgM Neutralizing Antibody (8A5)
EPT006	ELK Biotech	50ug	EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-IgA Neutralizing Antibody (8A5)
EPT018	ELK Biotech	50ug	EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody
100436-1	BPS Bioscience	50 µg	EUR 355
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody
100436-2	BPS Bioscience	100 µg	EUR 490
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-PD-1 Neutralizing Antibody, Biotin-labeled
71215	BPS Bioscience	100 µg	EUR 510
Description: Purified, recombinant, human anti-PD-1 (IgG1) antibody with C-terminal Avitag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-PD-L1 Neutralizing Antibody, Biotin-labeled
71214	BPS Bioscience	100 µg	EUR 510
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species.

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody (8A5)
EPT031	ELK Biotech	50ug	EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5)
EPT084	ELK Biotech	50ug	EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody (8A5)
EPT085	ELK Biotech	50ug	EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)
SAD-S35	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody
DL99726A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody
DL99726A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Anti-PCSK9 Neutralizing Antibody, (IgG1) Biotin-labeled
71216	BPS Bioscience	50 µg	EUR 530
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG1) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This antibody reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Anti-PCSK9 Neutralizing Antibody, (IgG4) Biotin-labeled
71217	BPS Bioscience	50 µg	EUR 515
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG4) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This protein reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)
SPD-M180	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Monoclonal NGF/proNGF Neutralizing Antibody Antibody
AMM06679G	Leading Biology	0.05mg	EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody
DL99727A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody
DL99727A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Rabbit anti-LukAB pAb (neutralizing)
0313-001	IBT Bioservices	500ug	EUR 486
Description: Related to: Staphylococcus Applications: Neutralization

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122)
S1N-M122	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122)
SPD-M162	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgA1 (AM122)
SPD-M58P1	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgA1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgA1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein.

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128)
SPD-M128	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (SPD-M128) is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Spike Neutralizing Antibody (Clone G10xA1) (SARS-CoV-2)
101326	BPS Bioscience	100 µg	EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience #78339).

Spike Neutralizing Antibody (Clone G10xA5) (SARS-CoV-2)
101327	BPS Bioscience	100 µg	EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience, #78339).

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2)
100792	BPS Bioscience	100 µg	EUR 460
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1)
100793	BPS Bioscience	100 µg	EUR 485
Description: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122)
SCT-M369	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (SCT-M369), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.

Neutralizing Solution
10750014-1	Bio-WORLD	1 L	EUR 42.29

Spike Neutralizing Antibody (Clone LxC1-G10) (SARS-CoV-2)
101246	BPS Bioscience	100 µg	EUR 545
Description: This human monoclonal antibody recognizes SARS-CoV-2 full-length spike proteins in the native trimeric conformation. This antibody cross-reacts with the wildtype (BPS Bioscience #100728) as well as the Alpha B.1.1.7 (BPS Bioscience #510334), Beta B.1.351 (BPS Bioscience #510333), Beta B.1.351Δ242-244 (BPS Bioscience #101091), Gamma P.1 (BPS Bioscience #100989), Delta B.1.617.2 (BPS Bioscience #101147) and Delta Plus B.1.617.2.1 (BPS Bioscience #101165) variant spike trimers [Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike Trimer: ACE2 Inhibitor Screening Kits (available for purchase).

SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit
D-1008	EpiGentek	EUR 359.70 EUR 570.90	48 Assays 96 Assays

D E Neutralizing Bt 500gm
281910	Scientific Laboratory Supplies	EACH	EUR 211.2

Classical Porcine Fever Virus Neutralizing Antibody ELISA Kit
RK04111	Abclonal	96T	EUR 625.2

Human-anti-SARS-CoV-2-antibody(Neutralizing)
E28F04204	EnoGene	N/A	EUR 1777.78
Description: N/A

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (MALS verified)
SPD-M265	ACROBIOSYSTEMS	100ug	EUR 5703.1
Description: The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG2 (AM359b) (MALS verified)
SPD-M400a	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG3 (AM359b) (MALS verified)
SPD-M401a	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.

Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (MALS verified)
SPD-M402a	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.

Cytomegalovirus gH Late Neutralizing Antigen (CMV-LA gH) Antibody
abx411285-02mg	Abbexa	0.2 mg	EUR 678

D/E NEUTRALIZING AGAR
D04-112-10kg	Alphabiosciences	10 kg	EUR 1843.2

D/E NEUTRALIZING AGAR
D04-112-2Kg	Alphabiosciences	2 Kg	EUR 447.6

D/E NEUTRALIZING AGAR
D04-112-500g	Alphabiosciences	500 g	EUR 165.6

Neutralizing Buffer 100gm
236210	Scientific Laboratory Supplies	EACH	EUR 85.2

Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)
BEB-Y12	ACROBIOSYSTEMS	100ug	EUR 2354
Description: Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.

D/E NEUTRALIZING BROTH
D04-115-10kg	Alphabiosciences	10 kg	EUR 1210.8

D/E NEUTRALIZING BROTH
D04-115-2kg	Alphabiosciences	2kg	EUR 309.6

D/E NEUTRALIZING BROTH
D04-115-500g	Alphabiosciences	500 g	EUR 128.4

D/E Neutralizing Broth
MED1144	Scientific Laboratory Supplies	PK50	EUR 60

PE-Labeled Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122)
SPD-PM226	ACROBIOSYSTEMS	25tests	EUR 2140
Description: PE-Labeled Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) is a PE-labeled chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in ELISA, this chimeric monoclonal antibody can bind the spike protein of all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2).

SARS-CoV-2 Neutralizing Monoclonal Antibody [DA0002]
A73683-100	EpiGentek	100 ul	EUR 506

Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N022	ACROBIOSYSTEMS	96tests	EUR 631.3
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 Neutralizing Antibody Quantitative Detection Kit (Spike RBD)
RAS-N044	ACROBIOSYSTEMS	96tests	EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses continual threat to human health due to rapid transmission worldwide.Anti-SARS-CoV-2 Neutralizing Antibody Quantitative Detection Kit (Spike RBD)to test the protective neutralizing antibody levels in post-vaccination serum or convalescent serum.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Trehalose free)
S1N-M12A1	ACROBIOSYSTEMS	100ug	EUR 270207.1
Description: Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) .

Horse Anti-Rabies Virus IgG (Fab2), neutralizing
RBV16-Fab2	Alpha Diagnostics	100 ul	EUR 534

NOVATest VAPERON Neutralizing Antibody Rapid Detection Kit (NOVA Test)
COVNA-503	Atlas Link Technology	20 Tests	Ask for price

Anti-SARS-CoV-2 (B.1.351) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N031	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (B.1.617.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N040	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 (B.1.1.529) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N056	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: As of Nov 29th, confirmed cases of a new variant of concern (VOC) B.1.1.529 have been reported in South Africa, Botswana and more than 12 other countries. Thanks to the rapid sequencing efforts of South African scientists, the whole world is now alerted about this potentially devastating lineage, which was assigned the name Omicron by WHO.Omicron is a highly divergent variant with a high number of mutations (26-35) in the spike. Identification of some familiar mutations that also appeared on other VOCs gives rises to concerns of its immune escape potential and higher transmissibility. To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 (B.1.1.7) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N028	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (P.1) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N034	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (BA.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N087	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: A more contagious subvariant of omicron, known as BA.2, is spreading across the globe and could soon become the dominant version of Covid-19.It's now the top variant in at least 18 countries and rapidly spreading, representing 35% of all new cases that have been genetically sequenced worldwide, up from 10 countries and 21% of cases the week before, according to new data from the World Health Organization. In the U.S, BA.2 currently makes up 3.8% of genetically sequenced Covid cases, according to the Centers for Disease Control and Prevention.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 (BA.2.12.1) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N120	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health, and it spreads quickly. It is helpful to develop the Anti SARS-CoV-2 neutralizing antibody titer serologic assay kit to test the protective neutralizing antibody level in serum.

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV)
100784	BPS Bioscience	100 µg	EUR 595
Description: SARS-CoV monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag™ fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. VHHs are single-domain antibodies from camelids.

Anti-SARS-CoV-2 (B.1.617.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike Trimer)
RAS-N041	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Cynomolgus IgG1 (AM122)
SPD-M201	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Cynomolgus IgG1 (AM122) (SPD-M201) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with Cynomolgus IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 Protein.

Anti-SARS-CoV-2 (BA.4 & BA.5) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)
RAS-N107	ACROBIOSYSTEMS	96tests	EUR 706.2
Description: The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health, and it spreads quickly. It is helpful to develop the Anti SARS-CoV-2 neutralizing antibody titer serologic assay kit to test the protective neutralizing antibody level in serum.

Biotinylated Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (MALS verified)
S1N-VM226	ACROBIOSYSTEMS	25ug	EUR 1647.8
Description: Biotinylated Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AM122) (S1N-VM226) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 Protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2).

Spike S1 Neutralizing Antibody (WT, B.1.1.7 and B.1.351 Variant) (Clone C-A11) (SARS-CoV-2)
101024	BPS Bioscience	100 µg	EUR 585
Description: This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

Human Monoclonal Anti-Chikungunya virus (CHIKV) E1_E2 protein IgG1 (neutralizing)
CHIKE13-M	Alpha Diagnostics	100 ul	EUR 578.4

Goat Anti-Human Respiratory Syncytial Virus (RSV) IgG, neutralizing
RSV12-S	Alpha Diagnostics	100 ul	EUR 548.4

Spike Trimer Neutralizing Antibody (B.1.617.2, B.1.617.2.1, WT and B.1.1.7 Variants) (Clone hC-A11) (SARS-CoV-2)
101061	BPS Bioscience	100 µg	EUR 475
Description: This antibody is a humanized monoclonal antibody which recognizes SARS-CoV-2 spike RBD and the full-length spike proteins in the native trimeric conformation. This antibody is derived from rabbit monoclonal C-A11 neutralizing antibody (BPS Bioscience, #101024). It cross-reacts with the wildtype as well as the B.1.617.2 (Delta Variant), B.1.617.2.1 (Delta PLUS Variant), B.1.1.7 (Alpha Variant) RBDs and spike protein trimers [See Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Sike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (available for purchase).

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled
100785-1	BPS Bioscience	50 µg	EUR 355
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled
100785-2	BPS Bioscience	100 µg	EUR 595
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Rabbit Anti-Poliomyelitis Virus 3 (Leon1,Ch,2ab strain) antiserum, neutralizing
POLV32-S	Alpha Diagnostics	100 ul	EUR 548.4

G. Pig anti-Poliomyelitis Virus 3 (sabin strain, native) antiserum, neutralizing
POLV33-S	Alpha Diagnostics	100 ul	EUR 548.4

SARS-CoV-2 Variants Neutralizing Antibody 6-plex Panel (Flow Cytometry Multiplex Bead Assay)
FCM-N04R	ACROBIOSYSTEMS	96tests	EUR 1187.7
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Rabbit Anti-Poliomyelitis Virus 1 (LSc,2ab strain) antiserum, neutralizing
POLV16-S	Alpha Diagnostics	100 ul	EUR 548.4

Horse Anti-C. tetani purified toxin/Toxoid IgG (Tetanus antitoxin, neutralizing, 300 IU/ml)
TTOX18-A	Alpha Diagnostics	100 ul	EUR 578.4

Horse Anti-C. tetani purified toxin/Toxoid IgG (Tetanus antitoxin, neutralizing, 750 IU/ml)
TTOX19-A	Alpha Diagnostics	100 ul	EUR 578.4

Mouse Monoclonal Anti-HIV-1 gp120 (PND, principal neutralizing domain) IgG
AB-15110	Alpha Diagnostics	100 ug	EUR 416.4

Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing)
MERS125-M	Alpha Diagnostics	100 ul	EUR 578.4

Rabbit Anti-Poliomyelitis Virus 2 (P712,Ch,2ab strain) antiserum, neutralizing
POLV22-S	Alpha Diagnostics	100 ul	EUR 548.4

G. Pig anti-Poliomyelitis Virus 2 (sabin strain, native) antiserum, neutralizing
POLV23-S	Alpha Diagnostics	100 ul	EUR 548.4

SARS-CoV-2 Omicron Subvariants Neutralizing Antibody 5-plex Panel (Flow Cytometry Multiplex Bead Assay)
FCM-N06R	ACROBIOSYSTEMS	96tests	EUR 1187.7
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.

Rabbit monoclonal Anti-MERS Spike protein (S1/RBD/MERS-RBD) IgG (Neutralizing)
MERS122-M	Alpha Diagnostics	100 ul	EUR 781.2

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 1)
RBVGP12-M	Alpha Diagnostics	100 ul	EUR 578.4

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 2)
RBVGP13-M	Alpha Diagnostics	100 ul	EUR 578.4

Horse Anti-C. tetani purified toxin/Toxoid IgG (Fab2), Tetanus antitoxin (neutralizing)
TTOX20-Fab2	Alpha Diagnostics	100 ul	EUR 534

Human Monoclonal Anti-Human Respiratory Syncytial Virus F protein (RSV-F, A2 strain) IgG1 (Neutralizing)
RSV16-M	Alpha Diagnostics	100 ul	EUR 578.4

Mouse-anti-COVID-19/SARS-CoV-2-Monoclonal-Antibody(Neutralizing)
E40MAV109	EnoGene	N/A	EUR 346.5
Description: N/A

Collectively, this high-resolution antibody repertoire evaluation demonstrated the influence evolution can have on BCRs in response to influenza virus vaccination, which may information future common influenza prophylactic approaches.